Related Experiment Video
Updated: Jun 23, 2026

07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
[Tumor Marker CA125: biochemical and molecular properties]
1Laboratoire de Biochimie, CHU Farhat-Hached, Sousse, Tunisie, Laboratoire de Biochimie, Faculté de Pharmacie, Monastir, Tunisie. bouanenehouda2@yahoo.fr
Bulletin Du Cancer
|May 14, 2009
Summary
Tumor marker CA125, a high-molecular-weight glycoprotein encoded by MUC16, is crucial for monitoring ovarian cancers. Its interactions with mesothelin and galectin may drive cancer progression and spread.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- The antigen carbohydrate CA125 is a well-established tumor marker for epithelial ovarian cancers.
- CA125 is a high-molecular-weight transmembrane glycoprotein, classified as a mucin with significant carbohydrate content (24-28%).
- The gene encoding CA125 is MUC16, characterized by its abundance of tandem repeats.
Purpose of the Study:
- To explore the secretion mechanisms of CA125, considering both soluble and cell-surface-attached forms.
- To investigate the molecular interactions of cell-surface CA125, specifically with mesothelin and galectin.
- To elucidate the role of these CA125 interactions in ovarian cancer stimulation and dissemination.
Main Methods:
- Review of existing hypotheses regarding CA125 secretion.
- Analysis of molecular interactions involving cell-surface CA125.
- Correlation of these interactions with ovarian cancer progression mechanisms.
Main Results:
- CA125 exists in both soluble and cell-surface-bound forms.
- Cell-surface CA125 engages in molecular interactions with proteins like mesothelin and galectin.
- These interactions are implicated in promoting ovarian cancer growth and metastasis.
Conclusions:
- CA125, encoded by MUC16, plays a multifaceted role in ovarian cancer beyond just being a marker.
- The molecular interactions of cell-surface CA125 are critical mediators of cancer cell behavior.
- Targeting these interactions presents a potential therapeutic avenue for ovarian cancer.
